AChRα10 Inhibitors

Chemical inhibitors of AChRα10 can act through a variety of mechanisms to prevent the activation of this receptor by its natural ligand, acetylcholine. α-Bungarotoxin is a potent inhibitor that binds irreversibly to AChRα10, occupying the acetylcholine binding site and thus blocking synaptic signal transmission. Similarly, Methyllycaconitine acts as an antagonist by attaching to the same recognition sites on the receptor, impeding the binding and response to acetylcholine. Dihydro-β-erythroidine achieves inhibition through competitive antagonism, sitting at the acetylcholine binding site and preventing activation of AChRα10. Tubocurarine also targets the acetylcholine binding site, but as a competitive antagonist, it obstructs the opening of the receptor's ion channel, which is necessary for conducting the ion flow that generates a nerve impulse.

Further inhibitory actions are seen with Hexamethonium, which can inhibit AChRα10 by binding to the receptor's ion channel pore, preventing ion permeation even when acetylcholine is present. Trimetaphan, another competitive antagonist, obstructs AChRα10 by denying acetylcholine the access it requires to activate the receptor. Chlorisondamine inhibits the receptor's ion channel from conducting ions, thereby halting the transduction of the synaptic signal. Bupropion serves as a noncompetitive antagonist, inhibiting AChRα10 by binding to an allosteric site, which results in the prevention of conformational changes essential for receptor activation. DhβE and MLA, both competitive antagonists, inhibit AChRα10 through occupation of the acetylcholine binding sites, ensuring that receptor activation does not occur. MeCamylamine, with its non-competitive antagonistic action, inhibits AChRα10 by attaching to sites within the ion channel, preventing the flow of ions. Each of these chemicals directly inhibits the function of AChRα10, curtailing its ability to propagate the neuronal signals that it would otherwise facilitate.